Dalia de la Fuente Vivas

  • c/ Albert Einstein, 22; 39011 Santander
  • dalia.delafuente@unican.es
  • 942 206 799 ext. 25907
  • Spatial Regulation of Ras-ERK Signals in Cancer
  • Cancer
  • Department of Cell & Molecular Signalling

Dalia received her first degree in Biology from the University of León (Spain, 2012).

After a short period working as graduate with her own proyect "New antidepressive tarjets", in Neurobiological basis of the mechanism group (IP, Ángel Pazos, IBBTEC, Cantabria), she acquired experience over more than one year, followed by a private company (Genetracer Biotech, Cantabria) funded by Banco Santander CRUE-CEPYME 2015 Grants.

She got interested in the biomedical research area obtaining Master`s degree of Initiation to Mental Health Research (University of Cantabria, 2015).

Since 2017, Dalia has been working as a predoctoral student in Spatial regulation of Ras-ERK signals in cancer Group (IP, Piero Crespo, IBBTEC, Cantabria) funded by CIBERONC.

​Spatial Regulation of Ras-ERK Signals in Cancer


Research lines 

    • Spatial regulation of Ras-ERK signals in physiological processes and in cancer
    • Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway


Funding

    • "Las interacciones entre proteínas scaffolds y dímeros de ERK como dianas antitumorales". BFU2011-23807. 2012-2015.
    • “Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019. 
    • Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
    • “Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”.  SAF-2015 63638R.  2016-2018.

isciiPiero.png

GRUPO FINANCIADO POR LA RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA EN CÁNCER DEL ISCIII/FEDER (RD12/0036/0033). 2012-2016  
Grupo incluído en el programa: Molecular Mechanisms in Cancer. Involucrado en el desarrollo de nuevas estratégias terapéuticas para inhibir rutas de señalización pro-tumorales.


Piero Crespo Baraja (IP)

View more

Lorena Agudo Ibáñez

View more

Vincenzo Cappitelli

View more

Rocío García Gómez

View more

Marta Morante Ezquerra

View more

Alicia Noriega Tato

View more

Laura Ruiz Peinado

View more